- Drink responsibly!: ride safely!1
- Drinking water: DOD has acted on some emerging contaminants but should improve internal reporting on regulatory compliance : report to Congressional committees1
- Drinking water: EPA should strengthen ongoing efforts to ensure that consumers are protected from lead contamination : report to congressional requesters1
- Driving better health outcomes through integrated care systems: the role of district councils1
- Driving value in Medicaid primary care: the role of shared support networks for physician practices1
- Drogen Spritzen kann eine saubere Sache sein: Wussten Sie eigentlich?1
- Drosera rotundifolia1
- Drs. Taylor and Rees performing their analysis1
- Drug Supply Chain Security Act implementation: identification of suspect product and notification1
- Drug and device manufacturer communications with payors, formulary committees, and similar entities: questions and answers : guidance for industry and review staff1
- Drug checking programs in the United States and internationally: environmental scan summary1
- Drug control policy: information on status of federal efforts and key issues for preventing illicit drug use : testimony before the Committee on Oversight and Government Reform, House of Representatives1
- Drug control: the Office of National Drug Control Policy should develop key planning elements to meet statutory requirements : report to Congressional addressees1
- Drug development: FDA's priority review voucher programs : report to Congressional committees1
- Drug development: Pathway for approving antibacterial and antifungal drugs for patients with limited treatment options is infrequently used : report to congressional committees1
- Drug discount program: federal oversight of compliance at 340B contract pharmacies needs improvement : report to Congressional requesters1
- Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives1
- Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate1
- Drug discount program: update on agency efforts to improve 340B program oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters1